While mutation of the tumor suppressor p53 presents with highest incidence among all cancers (48.3%), MM comprises only 21.5% p53 mutations (https://www.cbioportal.org; [32, 33] Fig. 1A; Table S2A, B), despite showing a highly progressive phenotype and chemoresistance. This evidence concerns the gene TP53 and Miyoshi myopathy.